at CNBC.com (Dec 8, 2014)
Momenta Pharmaceuticals (MNTA) gains 5.7% AH after announcing it has entered into a collaboration with Baxter (BAX) to develop a class of drugs called biosimilars. As part of the deal, Baxter will make a $33M up-front payment to Momenta related to the development of six drug compounds, and "may make additional payments over the next several years."
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Dec 2, 2014)
at MarketWatch.com (Oct 29, 2014)
at MarketWatch.com (Oct 20, 2014)
at MarketWatch.com (Aug 21, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs